2. Novel technology on isotope-free brachytherapy using miniature x-ray tube 2.1 System description 2.1.1 Axxent Xoft EBT controller and miniature x-ray source The EBT system consists of the Xoft controller, miniature x-ray source, and the treatment applicators. The Xoft controller, as shown in Figure 1 , includes a touch-screen monitor, USB port, barcode reader, pullback arm, x-ray source cooling system, Standard Imaging Well Chamber, and a Standard Imaging Max-4000 Electrometer. The pullback arm, as indicated in Figure 1 (a) and 1(b), has three adjustable joints and they are all adjustable for better positioning the source. There is a high voltage port on the arm for the source connection (not shown on the figure). The on-board well chamber ( Figure 2a ) and electrometer ( Figure 2b ) make the source pre-treatment calibration possible. The most essential part of this novel system is the design of the miniature x-ray source, as shown in Figure 3 . Figure 3a shows the overview of the x-ray source, which consists of an x-ray tube as small as a finger tip (Figure 3b ) located at the tip of a flexible cooling catheter (25 cm in length and 5.4 mm in diameter, as shown in Figure 3c ), a white mounting clip with a pair of cooling connection tubes (which need to be connected with the cooling system on the Xoft controller during the treatment), and a high voltage connector. Water circulating inside the catheter cools the surface of the source, this allows maximum air kerma strength of 1400 Gy/hr at 1cm for 50kV and 300 µA beam current 25 . The miniature x-ray tube is only 2.3 mm in diameter and 1.5 cm in length and generates 50kVp bremsstrahlung x-rays with a mean energy of 26.7 kV photons. 
Xoft surface applicators and target collimator
For treating superficial lesions on skin, Xoft surface applicators are used, as shown in Figure  4 . The cone connects to one end of the applicator source channel, whose other end connects to an adapter that is designed to lock the source in place for treatment (Figure 4a ). Four applicator cone sizes are available including 10 mm, 20 mm, 35 mm, and 50 mm. A disposable end cap that is made of 0.5mm plexiglas is used to cover the cone in order to protect it from the direct contact with patient and to ensure a flat treatment area. X-ray beams are further shaped for the clinical target with the custom-made lead shields (Axxent® FlexiShield Mini) (Figure 4b ), which are disposable, non-sterile, flexible devices with a circular shape (12.7 cm in diameter and 1mm in thickness). It has a lead equivalency of 0.45mm at 50kVp, which provides about a 30-fold reduction in radiation. 
Physics aspects 2.2.1 Dose rate output calibration and stability
The source nominal dose rate at the skin surface with the applicator needs to be calibrated prior to treatment. It is recommended to use the protocol AAPM TG-61 in-air method 32 for the soft x-ray dose calibration, using a soft x-ray parallel plate chamber (PTW T34013) mounted to a L-shaped in-air calibration fixture ( Figure 5 ), which is commercially available through Xoft, Inc. Dose to water at surface can be determined by:
Where M is the corrected ion chamber reading, raw TP pol ion elec M MP P P P  N k is the air-kerma calibration factor for the given beam's quality. B w is the backscatter factor which accounts for the effect of the phantom scatter and P stem,air is the stem correction factor which accounts for the change in photon scatter from the chamber stem between the calibration and measurement (mainly due to the change in field size 
Finally, the nominal dose rate to skin at surface can be calculated by , No min al Actual
Where med w C is the conversion factor from dose-to-water to dose-to-medium, which can be looked-up from the table provided in TG-61 
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The nominal skin surface dose-rate of 35mm applicator cone is reported to be 1.35 Gy/min averaged over sixteen sources, with a ±5% variation 31 . For the same source, the output variation is within 2%. Due to the differences in the design of the flattening filters and cone sizes, the dose rate output varies. The average dose-rates are 1.52, 1.39, 1.35, and 0.67 Gy/min for 10, 20, 35, and 50mm applicators. Smaller cone sizes produce higher dose rates, due to the design of the flattening filter and the in-field scattering from the applicator.
Field flatness and symmetry
The reported beam flatness and symmetry (mean and standard deviation) for ten sources over the central 80% of the field width are well within 5% from all four sizes of the applicator cones. With a flattening filter built in the applicator cone, it is possible to obtain a uniform dose distribution on the surface of the applicator as well as at a depth beneath the skin. As shown in Figure 6 (a), the radiation field was tightly conformed by the applicator cone. Film profiles (background subtracted) for five sources all normalized to the profile center at 100% are shown in Figure 6b and 6c. The dose penumbra region is smaller than 2.0 mm at surface, sharp enough to spare surrounding normal tissues. 
Percentage depth dose (PDD)
The factory data is provided for clinical use based on the measurements averaging over ten sources for all four applicators. Factory PDD data was obtained using a water tank with sealed ion-chamber and applicators ( Figure 7 ). Surface dose was obtained by extrapolation.
Skin dose is about 126%-174% for a standard prescription depth of 2-5 mm. For the treatment range up to 6 mm, the dose fall-off is more rapid for smaller cone size, except for 10mm size, which resides between 20 mm and 35 mm probably due to the scattered electron contamination, which is more significant with such a small size. 
Nominal SSD and correction factors
Low energy x-ray beam should also obey the inverse square law, Moreover, if an air gap is inevitable in a treatment setup, the correction factor for the dose output ( air CF ) can be calculated using the nominal SSD:
where d is the calculating depth. The presence of an air-gap greatly affects the output at the skin surface. The dose fall off can be higher than 10% when there is more than 1mm air gap. The nominal SSDs are determined to be 20 mm for the 10 mm cone, 20 mm cone and 35 mm cone; and the nominal SSD is 30 mm for the 50 mm cone. Note that the nominal SSD varies with different cones due to the different filter manufacturing. The cutouts made by the Xoft Axxent® Mini lead shield can be used to collimate the beam to accommodate the treatment area. Cutout correction factors ( cone CF ) need to be measured prior to the treatment by qualified personnel to correct for the output change due to the use of the lead collimation. It can be calculated by:
Measurements of the specific cutout factors were performed using the surface applicator QA test fixture ( Figure 8 ). The applicator QA text fixture consists of inserts for the ion chamber (left figure) and the applicator (right figure) . A custom-made plastic slab with a groove can be used to accommodate the parallel-plate chamber, so that the chamber surface is flush to the phantom surface. This fixture allows measurements with additional solid water slabs placed on top of the chamber and centrally fixed applicator. Fig. 8 . Surface applicator QA test fixture with the PTW T34013 parallel plate chamber centrally inserted under the applicator for shielded measurements.
Clinical management 2.3.1 Prescription and treatment time calculation
The treatment area was determined by physician as the visible tumor (i.e. gross tumor volume or GTV) plus estimated microscopic extension (i.e. clinical target volume or CTV), with an additional margin depending on tumor size (planning target volume or PTV). A smaller margin (typical 5 mm) than typically used with electron beam or 192 Ir HDR brachytherapy is recommended, given the beam flatness of the Xoft 35 mm surface applicator (with a mean and SD of 3.2%±1.2% as stated in the Xoft Axxent® system manual). Physicians make the selection of applicator cone size depending on the treatment area. Common prescription doses are 3 Gy per fraction to 45~48 Gy total for larger lesions or 5 Gy per fraction to 40 Gy total for smaller lesions. The prescription depth varies from 2 to 6 mm, depending on the characteristics of the tumor. Patient with lesion thicknesses larger than 6 mm generally should not be treated with EBT treatment, due to the rapid dose fall-off with depth. Very close contact should be maintained between the applicator end-cap and skin so that the air gaps can be eliminated. 
Cutout factors need to be pre-measured for each patient case since patients have very different target areas, as shown in Figure 9 , using the method mentioned in section B.4. Bolus materials have multiple purposes for skin cancer treatment including immobilizing the collimation material and attenuating radiation outside the treatment field. For cases shown in Figure 9a and 9b, bolus materials are used for filling the gap between the collimator cutouts and the mask in order to ensure minimum air gap and for protecting the scalp area behind the ear. Treatment time usually takes 4 to 6 minutes for each session. The source stays in one position inside the applicator throughout the entire session. In the early clinical application of this new technology there were no cases of interruption of treatment resulting from malfunction of the applicator or patient movements. Source arcing did occur a few times during a few treatments, leading to an interruption of the treatment and recalculation for the remaining dose. The air-kerma strength was re-measured prior to the continuation of the treatment using the on-board well chamber and electrometer. In all cases, the treatment was successfully continued and finished after replacing the source. 
Room setup and exposure to the personnel
In our clinic, patients lie on a flat "couch" (a linac table is what we use in our clinic) with clinically appropriate immobilization systems devised by the radiation therapists and physician to ensure minimal patient motion at applicator placement and during the treatment. For example, a thermoplastic facemask (WFR-Aquaplast, Avondale, PA) is normally used for lesions located on the face and other areas in the head and neck (Figure 10a ). Patient positioning is not essential in this type of treatment since physicians can visually locate the treatment area and accurately place the applicator (although it is preferable to have the applicator oriented downwards rather than upwards or horizontally when possible for ease of set-up and reproducibility). A 0.5 cm lead equivalent rolling shield (2 meter tall and 1 meter wide) is used to reduce radiation exposure to the therapy personnel (Figure 10b ). The therapy team can stay in the room and monitor the treatment through a small viewing window on the rolling shield. The room exposure measured with a survey meter was reported for three patients with the skin lesions located at their scalp, left ear, and left leg 31 . These three patients were scheduled on the same day for treatment using the same x-ray source. Seven positions in the treatment room were surveyed during the treatment session ( Figure 11 ). As shown in Table 1 , the highest room exposures were 70 mR/hr, 43 mR/hr, and 6.7 mR/hr at 1 m superior to the lesion for the scalp, left ear, and left leg. As expected, the further away from the source, the lower the exposure. The exposure rate was consistently at background reading (<1 mR/hr) behind the rolling shield. Therefore, the clinical personnel are safe and receive essentially no radiation behind the rolling shield. Table 1 . Room exposure at different locations during the treatment of several patient setups
Initial clinical experience and patient follow-up
Similar to isotope-based HDR brachytherapy, the primary radiation oncologist and a medical physicist are currently required to be present for each treatment. After patient is comfortably lying down on the table, the radiation oncologist directly visualizes the target location and places the applicator with minimal air gap and at an appropriate angle. The physicist and therapists help the physician to secure the applicator using a clamp system. As shown in Figure 12 , the surface applicator needs to be placed close to the target or pressing the collimator for various lesion locations, such as on the left ear, the left leg, and the scalp. As in Figures 13, 14 , and 15, most non-melanoma skin cancers responded fully to the treatment. During the course of treatment, most lesions demonstrated increased erythema. Many lesions became slightly ulcerated or turned into eschars in the first one to four weeks following the completion of treatment. However, by three to six months of follow up most cases showed resolution of acute radiodermatitis and no evidence of remaining malignancy. Due to the early stage of clinical practice using the surface applicators and EBT system, there is only one publication so far to provide the initial experience for treatment of 37 patients with 44 cutaneous malignancies in terms of tumor control, acute toxicity, and cosmesis 33 . No recurrences had been seen for a median of 4.1 months (range 1-9 months) follow-up, with acceptable acute toxicity and good to excellent early cosmesis.
Early clinical experience of EBT shows favorable tumor control as well as cosmetic outcomes. Using the hypofractionated approach, the treatment duration is short and convenient for patients. Direct visualization of the target location helps radiation oncologist to accurately place the applicator, thus accurately direct the radiation. 
Technical and clinical considerations 2.4.1 Dose output uncertainty
As suggested in TG-61, the in-air method is recommended for measuring the absorbed dose to water at surface for low energy x-rays with tube potential between 40 kV and 300 kV. The Xoft source has an operating voltage of 50 kV, which falls within this region. Based on equation (1), several factors need to be pre-determined for the surface dose measurements. Similar to TG-51 for high-energy external beam, the calibration factor N k and the electrometer correction 10, 20, 35 , and 50 mm cone sizes, respectively. The stem correction factor P stem,air is set to 1 if the change of field size and beam quality between the calibration and actual measurements is minimal. Including all calibration parameters, the combined uncertainty at the surface in low energy x-ray beams using the in-air calibration method is 5%. Since the other part of uncertainty associated with the clinical setup and immobilization during treatment can be considered negligible due to the ease and stability of the setup using this skin applicator system, the final uncertainty in the absorbed dose should satisfy a tolerance of ±5% 34 .
Treatment consideration
The presence and specific magnitude of electron contamination generated in air and on the inside surface of the treatment cone might contribute to an enhanced surface dose, which largely depends on the material from which the treatment cone is fabricated. A five-fold increase was reported in relative surface dose with lead lined treatment cones 35, 36 . The selection of an ionization chamber for a proper window thickness used in surface dose determination is crucial to the x-ray source calibration. The entrance window thickness should not be so thick that it absorbs low-energy photons nor so thin that it can be contaminated by photoelectrons. The surface points on the PDD curves provided by the company were determined by extrapolation. Its accuracy is questionable due to the possible effect of enhanced surface dose with the applicator cone. Further studies with Monte Carlo simulation are needed for accurately modeling the PDD in tissue with the surface applicators. It also implies that correction factors, i.e. cutout factors or air gap factors are more accurate if measured at depth. It is recommended that close contact between skin surface and applicator end-cap be maintained to avoid underdosing due to the presence of an air-gap. The effective SSD is different for different applicators, but it can be determined for all applicators by measuring the air-gap correction factors as we described above. For treatment areas where a flat surface is hard to achieve, thin bolus material can be use to facilitate the treatment. As to date, the largest available cone size is 50 mm in diameter for the Xoft surface applicators. This limits the application of EBT for lesions with a diameter larger than 40 mm. One possible solution is to combine multiple fields to cover the target. However, with the round shape of the field and manual positioning of the applicator, this technique might requires more practice and better design, to avoid overdosing or underdosing at the junction of two fields.
Room exposure to personnel
Room exposure varies with patient setups. As shown in Table 1 , the scalp case represents an extreme scenario where no lead collimation was used due to a large treatment area and a very loose contact with the skin (due to patient discomfort when the applicator was pressed onto the lesion). The left ear case has an oblique skin surface but the use of bolus and lead collimation helped to reduce radiation exposure to staff. The left leg case was a small lesion and had very flat skin surface and thus close contact was achieved. This case represents the other extreme. Even for the scalp case, where the room exposure was maximal, the survey meter reading was below 1 mR/hr behind the rolling shield. The rolling shield does effectively minimize radiation exposure to personnel when properly used. Moreover, the use of Flexi-shield or bolus significantly reduces the room exposure, thus is recommended when possible.
Comparison with isotope-based HDR brachytherapy
Overall, it has been shown that Xoft miniature x-ray source can produce comparable dose distribution for intracavitory brachytherapy treatment compared to 192 Ir source [26] [27] [28] . One major concern is the relatively more rapid dose fall off with distance in tissue compared to 192 Ir source, which results in a higher surface dose near the MammoSite balloon applicator for APBI treatment or the Vaginal cylinder applicator for endometrial treatment. This is due to the lower energy (50keV) emitted from the miniature x-ray tube, compared to the effective energy of about 380keV for 192 Ir 37 . The size of the source is also a limitation. The miniature x-ray source is 2.3 mm in diameter, and it has to be housed in a cooling catheter in order to maintain a long time function. The apparent size of the source is 5.4 mm in diameter, which is too large for interstitial brachytherapy treatments. However the economics and safety favor the use of EBT over 192 Ir, in terms of minimal shielding required, less regulations over radioactive materials, initial cost of the unit, etc. Favorable cosmetic outcomes and excellent local control (97~98% for primary tumors and 87% for recurrence) with minimal complications have been reported with isotope-based brachytherapy method for a follow-up study of 117 patients 8 . Clinical follow-up of a total of 85 patients have shown that the local control for the skin cancer using the isotope-based brachytherapy is 97%, with good cosmetic results (grade 1 (58%) and grade 2 (24%) acute skin toxicity) 22 . Since the electronic brachytherapy for skin cancer is still at its early stage for clinical management, patient follow-up reports are limited. Initial experience at University of Pittsburgh was published for treatment of 37 patients with 44 cutaneous malignancies using the electronic brachytherapy in terms of tumor control, acute toxicity, and cosmesis. No recurrences had been seen for a median of 4.1 months (range 1-9 months) follow-up, with acceptable acute toxicity and good to excellent early cosmesis 33 . We anticipate increased clinical applications of this technology in the near future.
Summary
The application of EBT for skin treatment is still relatively new and consequently is unfamiliar to many medical physicists and physicians. It is relatively simple to implement technically. With limited clinical experience and short follow-up it appears to be safe and effective for small non-melanoma skin cancers. Each source needs to be carefully calibrated with the surface applicator prior to treatment. The electronic brachytherapy is a feasible approach for treatment of non-melanoma skin cancer.
